LAUSANNE, Switzerland--(BUSINESS WIRE)--The Lausanne, Switzerland, based drug delivery company EffRx Pharmaceuticals SA (“EffRx”) and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.
